Candel Therapeutics, Inc. (NASDAQ:CADL) on Wednesday revealed final survival data from a phase 2a trial of CAN-2409 in ...

Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 ...

Durable complete response (CR) in a MCC patient treated with 15 mg/kg solnerstotug + cemiplimab. Patient continues on ...

ICI-based combinations are the preferred first-line therapy due to their proven superiority over TKI monotherapy, many patients were not receiving them,” the researchers wrote.

Discover Lantern Pharma's transformative 2024 journey in precision oncology with AI breakthroughs, global trial expansions, and key clinical milestones ...

GEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway and clinical sites confirmed  Additional data evaluating GEO-CM04S1 as ...

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, today announced it will present preclinical ...

Candel Therapeutics, Inc. (NASDAQ: CADL) shares are are trading lower Thursday after the company released final survival data from its phase 2a clinical trial of CAN-2409.

Pliant stock crashes 89% in three months following setbacks in the mid-stage study of its lead candidate, bexotegrast, for idiopathic pulmonary fibrosis.

Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the ...

Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...